Compare

Cerenome, Inc. vs Ensysce Biosciences, Inc. vs ProPhase Labs, Inc. vs Korro Bio, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearCerenome, Inc.
CNSY
Ensysce Biosciences, Inc.
ENSC
ProPhase Labs, Inc.
PRPH
Korro Bio, Inc.
KRRO
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$5.21M$5.07M$4.34M$6.39M
Revenue growth (YoY)-10.5%-2.8%-35.8%+181.5%
Gross marginn/an/a31.9%n/a
Operating margin-293.5%-202.1%-415.4%n/m
Net margin-429.4%-200.8%-339.3%n/m
Net income-$22.39M-$10.18M-$14.74M-$117.26M
EPS (Diluted)-$0.29-$3.98-$1.74-$12.48
Operating cash flow-$20.77M-$7.81M-$8.34M-$78.56M
Free cash flow-$20.84M-$7.93M-$8.34M-$79.08M
Cash & equivalents$4.26M$4.31M$90.0K$21.82M
Total assets$16.32M$7.45M$59.87M$113.51M
Total liabilities$12.33M$4.57M$56.36M$62.07M
Shareholders' equity$4.00M$3.21M$3.51M$51.44M
Return on year-end equity-560.2%-316.6%-420.3%-228.0%
Shares outstanding138.68M4.57M8.97M9.42M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearCerenome, Inc.Ensysce Biosciences, Inc.ProPhase Labs, Inc.Korro Bio, Inc.
Latest$5.21M
Ended 2025-12-31
$5.07M
Ended 2025-12-31
$4.34M
Ended 2025-12-31
$6.39M
Ended 2025-12-31
1 year earlier$5.82M
Ended 2024-12-31
$5.21M
Ended 2024-12-31
$6.77M
Ended 2024-12-31
$2.27M
Ended 2024-12-31
2 years earlier$4.91M
Ended 2023-12-31
$2.23M
Ended 2023-12-31
$34.98M
Ended 2023-12-31
$0
Ended 2023-12-31
3 years earliern/a$2.52M
Ended 2022-12-31
$122.65M
Ended 2022-12-31
n/a
4 years earliern/a$3.53M
Ended 2021-12-31
$79.04M
Ended 2021-12-31
n/a